CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) —
Genocea Biosciences, Inc.
(NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the virtual 11
th
Annual SVB Leerink Global Healthcare Conference on Thursday, February 17
th
at 10:40 A.M. ET.
A live webcast of the presentation will be available in the “Events and Presentations” tab of the investor relations section of the Genocea website at
https://ir.genocea.com/events-presentations
. A replay of the webcast will be archived for 90 days following the presentation.
About Genocea Biosciences, Inc.
Genocea’s mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Our proprietary ATLAS™ platform can comprehensively profile each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, Inhibigens™, that drive pro-tumor immune responses. We are conducting a Phase 1/2a clinical trial for GEN-011, our investigational adoptive T cell therapy comprising neoantigen-targeted peripheral cells. We continue to monitor patients in our phase 1/2a clinical trial for GEN-009, our investigational neoantigen vaccine. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in optimizing antigen selection for therapies across a number of diseases. To learn more, please visit
https://www.genocea.com
.
Investor Contact:
Dan Ferry
617-430-7576
[email protected]
